The exon 8-containing prosaposin gene splice variant is dispensable for mouse development, lysosomal function, and secretion

Molecular and Cellular Biology

Volumn 25, Issue 6, 2005, Pages 2431-2440

  Cohen, Tsadok ^a   Auerbach, Wojtek ^c   Ravid, Liat ^a   Bodennec, Jacques ^b   Fein, Amos ^a   Futerman, Anthony H ^b   Joyner, Alexandra L ^c   Horowitz, Mia ^a  

^a TEL AVIV UNIVERSITY   (Israel)

^b WEIZMANN INSTITUTE OF SCIENCE   (Israel)

^c NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ASPARTIC ACID; CERAMIDE; GANGLIOSIDE; GLUTAMINE; GLYCOSPHINGOLIPID; HYDROLASE; ISOPROTEIN; LYSOSOME ENZYME; NEUROTROPHIC FACTOR; PHOSPHOLIPID; PROSAPOSIN; SPHINGOLIPID; SPHINGOLIPID ACTIVATOR PROTEIN; SULFATIDE;

ALTERNATIVE RNA SPLICING; ANIMAL CELL; ANIMAL TISSUE; ARTICLE; BRAIN DEVELOPMENT; CONTROLLED STUDY; ENZYME ACTIVITY; EXON; FERTILIZATION; FIBROBLAST; GENE DELETION; HYDROLYSIS; LIPID METABOLISM; LIPID STORAGE; LYSOSOME; MALE; MOUSE; MOUSE MUTANT; NERVE FUNCTION; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN SECRETION; PROTEIN TERTIARY STRUCTURE;

ALTERNATIVE SPLICING; ANIMALS; ASPARAGINE; EMBRYO; EXONS; FERTILITY; GLUTAMINE; LIPID METABOLISM; LIPIDS; LYSOSOMES; MALE; MICE; MICE, MUTANT STRAINS; PROTEIN ISOFORMS; RNA, MESSENGER; SAPOSINS; SEQUENCE DELETION; STEM CELLS; TESTIS; TISSUE DISTRIBUTION;

EID: 14844363960     PISSN: 02707306     EISSN: None     Source Type: Journal    
DOI: 10.1128/MCB.25.6.2431-2440.2005     Document Type: Article

References (68)

1. Ahn, V. E., K. F. Faull, J. P. Whitelegge, A. L. Fluharty, and G. G. Prive. 2003. Crystal structure of saposin B reveals a dimeric shell for lipid binding. Proc. Natl. Acad. Sci. USA 100:38-43.
2. Amann, R. P., R. H. Hammerstedt, and R. B. Shabanowitz. 1999. Exposure of human, boar, or bull sperm to a synthetic peptide increases binding to an egg-membrane substrate. J. Androl. 20:34-41.
3. Arundine, M., and M. Tymianski. 2004. Molecular mechanisms of glutamate-dependent neurodegeneration in ischemia and traumatic brain injury. Cell. Mol. Life Sci. 61:657-668.
4. Bodennec, J., O. Koul, I. Aguado, G. Brichon, G. Zwingelstein, and J. Portoukalian. 2000. A procedure for fractionation of sphingolipid classes by solid-phase extraction on aminopropyl cartridges. J. Lipid Res. 41:1524-1531.
5. 3H]acetic anhydride. J. Lipid Res. 44:1413-1419.
6. Bradford, M. M. 1976. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 72:248-254.
7. Cohen, T., L. Ravid, N. Altman, L. Madar-Shapiro, A. Fein, M. Weil, and M. Horowitz. 2004. Conservation of expression and alternative splicing in the prosaposin gene. Brain Res. Mol. Brain Res. 129:8-19.
8. Fischer, G., and H. Jatzkewitz. 1977. The activator of cerebroside sulphatase. Binding studies with enzyme and substrate demonstrating the detergent function of the activator protein. Biochim. Biophys. Acta 481:561-572.
9. Folch, J., M. Lees, and G. H. Sloane Stanley. 1957. A simple method for the isolation and purification of total lipids from animal tissues. J. Biol. Chem. 226:497-509.
10. Fu, Q., G. S. Carson, M. Hiraiwa, M. Grafe, Y. Kishimoto, and J. S. O'Brien. 1994. Occurrence of prosaposin as a neuronal surface membrane component. J. Mol. Neurosci. 5:59-67.
11. Fujita, N., K. Suzuki, M. T. Vanier, B. Popko, N. Maeda, A. Klein, M. Henseler, K. Sandhoff, H. Nakayasu, and K. Suzuki. 1996. Targeted disruption of the mouse sphingolipid activator protein gene: a complex phenotype, including severe leukodystrophy and wide-spread storage of multiple sphingolipids. Hum. Mol. Genet. 5:711-725.
12. Ham, D. 2003. Structural requirements for lysosomal targeting of the prosaposin precursor protein. Cell Biol. Int. 27:675-687.
13. Hammerstedt, R. H., P. G. Cramer, G. F. Barbate, R. P. Amann, J. S. O'Brien, and M. D. Griswold. 2001. A fragment of prosaposin (SGP-1) from rooster sperm promotes sperm-egg binding and improves fertility in chickens. J. Androl. 22:361-375.
14. Hanks, M., W. Wurst, L. Anson-Cartwright, A. B. Auerbach, and A. L. Joyner. 1995. Rescue of the En-1 mutant phenotype by replacement of En-1 with En-2. Science 269:679-682.
15. Harzer, K., B. C. Paton, A. Poulos, B. Kustermann-Kuhn, W. Roggendorf, T. Grisar, and M. Popp. 1989. Sphingolipid activator protein deficiency in a 16-week-old atypical Gaucher disease patient and his fetal sibling: biochemical signs of combined sphingolipidoses. Eur. J. Pediatr. 149:31-39.
16. Henseler, M., A. Klein, G. J. Glombitza, K. Suziki, and K. Sandhoff. 1996. Expression of the three alternative forms of the sphingolipid activator protein precursor in baby hamster kidney cells and functional assays in a cell culture system. J. Biol. Chem. 271:8416-8423.
17. Hineno, T., A. Sano, K. Kondoh, S. Ueno, Y. Kakimoto, and K. Yoshida. 1991. Secretion of sphingolipid hydrolase activator precursor, prosaposin. Biochem. Biophys. Res. Commun. 176:668-674.
18. Hiraiwa, M., W. M. Cam pana, A. P. Mizisin, L. Mohiuddin, and J. S. O'Brien. 1999. Prosaposin: a myelinotrophic protein that promotes expression of myelin constituents and is secreted after nerve injury. Glia 26:353-360.
19. Hiraiwa, M., J. Liu, A. G. Lu, C. Y. Wang, R. Misasi, T. Yamauchi, I. Hozumi, T. Inuzuka, and J. S. O'Brien. 2003. Regulation of gene expression in response to brain injury: enhanced expression and alternative splicing of rat prosaposin (SGP-1) mRNA in injured brain. J. Neurotrauma 20:755-765.
20. Hiraiwa, M., J. S. O'Brien, Y. Kishimoto, M. Galdzicka, A. L. Fluharty, E. I. Ginns, and B. M. Martin. 1993. Isolation, characterization, and proteolysis of human prosaposin, the precursor of saposins (sphingolipid activator proteins). Arch. Biochem. Biophys. 304:110-116.
21. Hiraiwa, M., S. Soeda, Y. Kishimoto, and J. S. O'Brien. 1992. Binding and transport of gangliosides by prosaposin. Proc. Natl. Acad. Sci. USA 89:11254-11258.
22. Hiraiwa, M., E. M. Taylor, W. M. Campana, S. J. Darin, and J. S. O'Brien. 1997. Cell death prevention, mitogen-activated protein kinase stimulation, and increased sulfatide concentrations in Schwann cells and oligodendrocytes by prosaposin and prosaptides. Proc. Natl. Acad. Sci. USA 94:4778-4781.
23. Holtschmidt, H., K. Sandhoff, H. Y. Kwon, K. Harzer, T. Nakano, and K. Suzuki. 1991. Sulfatide activator protein. Alternative splicing that generates three mRNAs and a newly found mutation responsible for a clinical disease. J. Biol. Chem. 266:7556-7560.
24. Hozumi, I., M. Hiraiwa, T. Inuzuka, Y. Yoneoka, K. Akiyama, R. Tanaka, K. Kikugawa, R. Nakano, S. Tsuji, and J. S. O'Brien. 1999. Administration of prosaposin ameliorates spatial learning disturbance and reduces cavity formation following stab wounds in rat brain. Neurosci. Lett. 267:73-76.
25. Huettner, J. E. 2003. Kainate receptors and synaptic transmission. Prog. Neurobiol. 70:387-407.
26. Hulkova, H., M. Cervenkova, J. Ledvinova, M. Tochackova, M. Hrebicek, H. Poupetova, A. Befekadu, L. Berna, B. C. Paton, K. Harzer, A. Boor, F. Smid, and M. Elleder. 2001. A novel mutation in the coding region of the prosaposin gene leads to a complete deficiency of prosaposin and saposins, and is associated with a complex sphingolipidosis dominated by lactosylceramide accumulation. Hum. Mol. Genet. 10:927-940.
27. Kishimoto, Y., M. Hiraiwa, and J. S. O'Brien. 1992. Saposins: structure, function, distribution, and molecular genetics. J. Lipid Res. 33:1255-1267.
28. Klein, A., M. Henseler, C. Klein, K. Suzuki, K. Harzer, and K. Sandhoff. 1994. Sphingolipid activator protein D (Sap-D) stimulates the lysosomal degradation of ceramide in-vivo. Biochem. Biophys. Res. Commun. 200:1440-1448.
29. Kondoh, K., T. Hineno, A. Sano, and Y. Kakimoto. 1991. Isolation and characterization of prosaposin from human milk. Biochem. Biophys. Res. Commun. 181:286-292.
30. Kotani, Y., S. Matsuda, M. Sakanaka, K. Kondoh, S. Ueno, and A. Sano. 1996. Prosaposin facilitates sciatic nerve regeneration in vivo. J. Neurochem. 66:2019-2025.
31. Kretz, K. A., G. S. Carson, S. Morimoto, Y. Kishimoto, A. L. Fluharty, and J. S. O'Brien. 1990. Characterization of a mutation in a family with saposin B deficiency: a glycosylation site defect. Proc. Natl. Acad. Sci. USA 87:2541-2544.
32. Lamontagne, S., and M. Potier. 1994. Modulation of human saposin B sphingolipid-binding specificity by alternative splicing. A study with saposin B-derived synthetic peptides. J. Biol. Chem. 269:20528-20532.
33. Leonova, T., X. Qi, A. Bencosme, E. Ponce, Y. Sun, and G. A. Grabowski. 1996. Proteolytic processing patterns of prosaposin in insect and mammalian cells. J. Biol. Chem. 271:17312-17320.
34. Li Song, D., and A. L. Joyner. 2000. Two Pax2/5/8-binding sites in Engrailed2 are required for proper initiation of endogenous mid-hindbrain expression. Mech. Dev. 90:155-165.
35. Madar-Shapiro, L., M. Pasmanik-Chor, A. M. Vaccaro, T. Dinur, A. Dagan, S. Gatt, and M. Horowitz. 1999. Importance of splicing for prosaposin sorting. Biochem. J. 337:433-443.
36. Matsuda, J., M. Kido, K. Tadano-Aritomi, I. Ishizuka, K. Tominaga, K. Toida, E. Takeda, K. Suzuki, and Y. Kuroda. 2004. Mutation in saposin D domain of sphingolipid activator protein gene causes urinary system defects and cerebellar Purkinje cell degeneration with accumulation of hydroxy fatty acid-containing ceramide in the mouse. Hum. Mol. Genet. 13:2709-2723.
37. Matsuda, J., M. T. Vanier, Y. Saito, J. Tohyama, and K. Suzuki. 2001. A mutation in the saposin A domain of the sphingolipid activator protein (prosaposin) gene results in a late-onset, chronic form of globoid cell leukodystrophy in the mouse. Hum. Mol. Genet. 10:1191-1199.
38. McKinnell, C., and R. M. Sharpe. 1997. Regulation of the secretion and synthesis of rat Sertoli cell SGP-1, SGP-2 and CP-2 by elongate spermatids. Int. J. Androl. 20:171-179.
39. Misasi, R., M. Sorice, T. Garofalo, T. Griggi, W. M. Campana, M. Giammatteo, A. Pavan, M. Hiraiwa, G. M. Pontieri, and J. S. O'Brien. 1998. Colocalization and complex formation between prosaposin and monosialoganglioside GM3 in neural cells. J. Neurochem. 71:2313-2321.
40. Morales, C. R., and H. Badran. 2003. Prosaposin ablation inactivates the MAPK and Akt signaling pathways and interferes with the development of the prostate gland. Asian J. Androl. 5:57-63.
41. Morales, C. R., N. Hay, M. El-Alfy, and Q. Zhao. 1998. Distribution of mouse sulfated glycoprotein-1 (prosaposin) in the testis and other tissues. J. Androl. 19:156-164.
42. Morales, C. R., Q. Zhao, M. El-Alfy, and K. Suzuki. 2000. Targeted drsruption of the mouse prosaposin gene affects the development of the prostate gland and other male reproductive organs. J. Androl. 21:765-775.
43. Morita, F., T. C. Wen, J. Tanaka, R. Hata, J. Desaki, K. Sato, K. Nakata, Y. J. Ma, and M. Sakanaka. 2001. Protective effect of a prosaposin-derived. 18-mer peptide on slowly progressive neuronal degeneration after brief ischemia. J. Cereb. Blood Flow Metab. 21:1295-1302.
44. Nakano, T., K. Sandhoff, J. Stumper, H. Christomanou, and K. Suzuki. 1989. Structure of full-length cDNA coding for sulfatide activator, a co-beta-glucosidase and two other homologous proteins: two alternate forms of the sulfatide activator. J. Biochem. (Tokyo) 105:152-154.
45. O'Brien, J. S., G. S. Carson, H. C. Seo, M. Hiraiwa, and Y. Kishimoto. 1994. Identification of prosaposin as a neurotrophic factor. Proc. Natl. Acad. Sci. USA 91:9593-9596.
46. Plowman, S. J., D. J. Williamson, M. J. O'Sullivan, J. Doig, A. M. Ritchie, D. J. Harrison, D. W. Melton, M. J. Arends, M. L. Hooper, and C. E. Patek. 2003. While K-ras is essential for mouse development, expression of the K-ras 4A splice variant is dispensable. Mol. Cell. Biol. 23:9245-9250.
47. Rafi, M. A., G. de Gala, X. L. Zhang, and D. A. Wenger. 1993. Mutational analysis in a patient with a variant form of Gaucher disease caused by SAP-2 deficiency. Somat. Cell Mol. Genet. 19:1-7.
48. Rafi, M. A., X. L. Zhang, G. DeGala, and D. A. Wenger. 1990. Detection of a point mutation in sphingolipid activator protein-1 mRNA in patients with a variant form of metachromatic leukodystrophy. Biochem. Biophys. Res. Commun. 166:1017-1023.
49. Regis, S., M. Filocamo, F. Corsolini, F. Caroli, J. L. Keulemans, O. P. van Diggelen, and R. Gatti. 1999. An Asn > Lys substitution in saposin B involving a conserved amino acidic residue and leading to the loss of the single N-glycosylation site in a patient with metachromatic leukodystrophy and normal arylsulphatase A activity. Eur. J. Hum. Genet. 7:125-130.
50. Rende, M., E. Brizi, R. Donato, C. Provenzano, R. Bruno, A. P. Mizisin, R. S. Garrett, N. A. Calcutt, W. M. Campana, and J. S. O'Brien. 2001. Prosaposin is immunolocalized to muscle and prosaptides promote myoblast fusion and attenuate loss of muscle mass after nerve injury. Muscle Nerve 24:799-808.
51. Sandhoff, K., K. Harzer, and W. Furst. 1995. Sphingolipid activator proteins, p. 2427-2441. In S. Scriber, A. Beaudet, W. Sly, and D. Valle (ed.), The metabolic and molecular basis of inherited disease, 7th ed. McGraw-Hill, New York, N.Y.
52. Sandhoff, K., and T. Kolter. 2003. Biosynthesis and degradation of mammalian glycosphingolipids. Philos. Trans. R. Soc. Lond. B Biol. Sci. 358:847-861.
53. Sano, A., T. Hineno, T. Mizuno, K. Kondoh, S. Ueno, Y. Kakimoto, and K. Inui. 1989. Sphingolipid hydrolase activator proteins and their precursors. Biochem. Biophys. Res. Commun. 165:1191-1197.
54. Sano, A., S. Matsuda, T. C. Wen, Y. Kotani, K. Kondoh, S. Ueno, Y. Kakimoto, H. Yoshimura, and M. Sakanaka. 1994. Protection by prosaposin against ischemia-induced learning disability and neuronal loss. Biochem. Biophys. Res. Commun. 204:994-1000.
55. Schlote, W., K. Harzer, H. Christomanou, B. C. Paton, B. Kustermann-Kuhn, B. Schmid, J. Seeger, U. Beudt, I. Schuster, and U. Langenbeck. 1991. Sphingolipid activator protein 1 deficiency in metachromatic leucodystrophy with normal arylsulphatase A activity. A clinical, morphological, biochemical, and immunological study. Eur. J. Pediatr. 150:584-591.
56. Schnabel, D., M. Schroder, W. Furst, A. Klein, R. Hurwitz, T. Zenk, J. Weber, K. Harzer, B. C. Paton, A. Poulos, K. Suzuki, and K. Sandhoff. 1992. Simultaneous deficiency of sphingolipid activator proteins 1 and 2 is caused by a mutation in the initiation codon of their common gene. J. Biol. Chem. 267:3312-3315.
57. Schnabel, D., M. Schroder, and K. Sandhoff. 1991. Mutation in the sphingolipid activator protein 2 in a patient with a variant of Gaucher disease. FEBS Lett. 284:57-59.
58. Sprecher-Levy, H., A. Orr-Urtreger, P. Lonai, and M. Horowitz. 1993. Murine prosaposin: expression in the reproductive system of a gene implicated in human genetic diseases. Cell. Mol. Biol. (Noisy-Le-Grand) 39:287-299.
59. Sylvester, S. R., C. Morales, R. Oko, and M. D. Griswold. 1989. Sulfated glycoprotein-1 (saposin precursor) in the reproductive tract of the male rat. Biol. Reprod. 41:941-948.
60. Tsuboi, K., M. Hiraiwa, and J. S. O'Brien. 1998. Prosaposin prevents programmed cell death of rat cerebellar granule neurons in culture. Brain Res. Dev. Brain Res. 110:249-255.
61. Wells, M. A., and J. C. Dittmer. 1963. The use of Sephadex for the removal of nonlipid contaminants from lipid extracts. Biochemistry 172:1259-1263.
62. White, J. K., W. Auerbach, M. P. Duyao, J. P. Vonsattel, J. F. Gusella, A. L. Joyner, and M. E. MacDonald. 1997. Huntingtin is required for neurogenesis and is not impaired by the Huntington's disease CAG expansion. Nat. Genet. 17:404-410.
63. Wrobe, D., M. Henseler, S. Huettler, S. I. Pascual Pascual, A. Chabas, and K. Sandhoff. 2000. A non-glycosylated and functionally deficient mutant (N215H) of the sphingolipid activator protein B (SAP-B) in a novel case of metachromatic leukodystrophy (MLD). J. Inherit. Metab. Dis. 23:63-76.
64. Wurst, W., and A. L. Joyner. 1993. Production of targeted embryonic stem cell clones, p. 33-61. In A. L. Joyner (ed.), Gene targeting: a practical approach. IRL Press, Oxford, United Kingdom.
65. Yaffe, D., and O. Saxel. 1977. Serial passaging and differentiation of myogenic cells isolated from dystrophic mouse muscle. Nature 270:725-727.
66. Yagi, T., J. Matsuda, S. Takikita, I. Mohri, and K. Suzuki. 2004. Comparative clinico-pathological study of saposin-A-deficient (SAP-A-/-) and Twitcher mice. J. Neuropathol. Exp. Neurol. 63:721-734.
67. Zhang, X. L., M. A. Rafi, G. DeGala, and D. A. Wenger. 1991. The mechanism for a 33-nucleotide insertion in mRNA causing sphingolipid activator protein (SAP-1)-deficient metachromatic leukodystrophy. Hum. Genet. 87:211-215.
68. Zhao, Q., N. Hay, and C. R. Morales. 1997. Structural analysis of the mouse prosaposin (SGP-1) gene reveals the presence of an exon that is alternatively spliced in transcribed mRNAs. Mol. Reprod. Dev. 48:1-8.